Compare Stocks: PEPG, DSGN, PRME, and OLMA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DSGN Design Therapeutics	$11.65 +1.4%	$13.83	$5.28 ▼ $17.25	$729.08M	1.68	748,639 shs	356,593 shs
OLMA Olema Pharmaceuticals	$7.82	$10.07	$6.65 ▼ $36.26	$684.23M	2	1.35 million shs	758,249 shs
PEPG PepGen	$2.62 +10.1%	$2.81	$1.31 ▼ $7.80	$181.46M	2.01	806,892 shs	603,693 shs
PRME Prime Medicine	$3.99 +11.5%	$3.30	$2.67 ▼ $6.65	$723.69M	2.37	4.51 million shs	8.06 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DSGN Design Therapeutics	0.00%	-5.59%	-21.28%	-23.30%	+67.87%
OLMA Olema Pharmaceuticals	0.00%	-4.98%	-26.85%	-34.34%	-27.12%
PEPG PepGen	0.00%	+14.91%	-13.25%	+11.97%	-46.20%
PRME Prime Medicine	0.00%	+33.89%	+19.10%	+5.56%	-38.14%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DSGN Design Therapeutics	$11.65 +1.4%	$13.83	$5.28 ▼ $17.25	$729.08M	1.68	748,639 shs	356,593 shs
OLMA Olema Pharmaceuticals	$7.82	$10.07	$6.65 ▼ $36.26	$684.23M	2	1.35 million shs	758,249 shs
PEPG PepGen	$2.62 +10.1%	$2.81	$1.31 ▼ $7.80	$181.46M	2.01	806,892 shs	603,693 shs
PRME Prime Medicine	$3.99 +11.5%	$3.30	$2.67 ▼ $6.65	$723.69M	2.37	4.51 million shs	8.06 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DSGN Design Therapeutics	0.00%	-5.59%	-21.28%	-23.30%	+67.87%
OLMA Olema Pharmaceuticals	0.00%	-4.98%	-26.85%	-34.34%	-27.12%
PEPG PepGen	0.00%	+14.91%	-13.25%	+11.97%	-46.20%
PRME Prime Medicine	0.00%	+33.89%	+19.10%	+5.56%	-38.14%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DSGN Design Therapeutics	2.89	Moderate Buy	$17.86	53.28% Upside
OLMA Olema Pharmaceuticals	2.77	Moderate Buy	$40.60	419.18% Upside
PEPG PepGen	2.67	Moderate Buy	$11.40	335.11% Upside
PRME Prime Medicine	2.90	Moderate Buy	$7.47	87.27% Upside

Current Analyst Ratings Breakdown

Latest PEPG, DSGN, PRME, and OLMA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/2/2026	DSGN Design Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$26.00
10/2/2026	DSGN Design Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$26.00
9/28/2026	PRME Prime Medicine	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
9/25/2026	PRME Prime Medicine	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
9/25/2026	PRME Prime Medicine	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$7.00
9/22/2026	PEPG PepGen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/21/2026	OLMA Olema Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/14/2026	OLMA Olema Pharmaceuticals	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$48.00 ➝ $30.00
9/9/2026	PEPG PepGen	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/31/2026	OLMA Olema Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/31/2026	PRME Prime Medicine	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 10/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	$3.73 per share	N/A
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	$5.88 per share	N/A
PEPG PepGen	N/A	N/A	N/A	N/A	$2.14 per share	N/A
PRME Prime Medicine	$4.63M	156.31	N/A	N/A	$0.67 per share	5.96

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DSGN Design Therapeutics	-$69.79M	-$1.18	N/A	N/A	N/A	N/A	-34.03%	-32.05%	11/4/2026 (Estimated)
OLMA Olema Pharmaceuticals	-$162.45M	-$2.12	N/A	N/A	N/A	N/A	-48.26%	-43.04%	11/9/2026 (Estimated)
PEPG PepGen	-$89.65M	-$1.31	N/A	N/A	N/A	N/A	-51.01%	-43.49%	11/11/2026 (Estimated)
PRME Prime Medicine	-$201.14M	-$1.06	N/A	N/A	N/A	-4,613.11%	-188.27%	-59.11%	N/A

Latest PEPG, DSGN, PRME, and OLMA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/4/2026	Q3 2026	DSGN Design Therapeutics	-$0.38	N/A	N/A	N/A	N/A	N/A
8/10/2026	Q2 2026	OLMA Olema Pharmaceuticals	-$0.5515	-$0.61	-$0.0585	-$0.61	N/A	N/A
8/6/2026	Q2 2026	PEPG PepGen	-$0.2845	-$0.26	+$0.0245	-$0.26	N/A	N/A
8/6/2026	Q2 2026	PRME Prime Medicine	-$0.24	-$0.24	N/A	-$0.24	$4.40 million	$1.15 million
8/3/2026	Q2 2026	DSGN Design Therapeutics	-$0.3443	-$0.32	+$0.0243	-$0.32	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	N/A
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PEPG PepGen	N/A	N/A	N/A	N/A	N/A
PRME Prime Medicine	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DSGN Design Therapeutics	N/A	18.86	18.86
OLMA Olema Pharmaceuticals	0.01	8.86	8.86
PEPG PepGen	N/A	13.36	13.36
PRME Prime Medicine	N/A	3.05	3.05

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DSGN Design Therapeutics	56.64%
OLMA Olema Pharmaceuticals	91.78%
PEPG PepGen	58.01%
PRME Prime Medicine	70.37%

Insider Ownership

Company	Insider Ownership
DSGN Design Therapeutics	17.10%
OLMA Olema Pharmaceuticals	12.56%
PEPG PepGen	1.30%
PRME Prime Medicine	16.04%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DSGN Design Therapeutics	55	62.58 million	51.88 million	Optionable
OLMA Olema Pharmaceuticals	150	87.50 million	76.51 million	Optionable
PEPG PepGen	57	69.26 million	68.36 million	Not Optionable
PRME Prime Medicine	146	181.38 million	152.28 million	N/A

PEPG, DSGN, PRME, and OLMA Headlines

Recent News About These Companies

Prime Medicine (NASDAQ:PRME) Stock Falls 7.6% - Here's Why

October 8 at 12:59 PM | marketbeat.com

Prime Medicine (NASDAQ:PRME) Stock Jumps 3.5% - Here's Why

October 7, 2026 | marketbeat.com

Prime Medicine, Inc. Doses First Patient In Global Phase 1/2 Clinical Trial Of PM577a For H1069Q-Mutated Wilson Disease

October 6, 2026 | marketscreener.comM

Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX) and Prime Medicine, Inc. (PRME)

October 6, 2026 | theglobeandmail.com

Prime Medicine (NASDAQ:PRME) Shares Gap Up - Here's Why

October 6, 2026 | marketbeat.com

Prime Medicine Doses First Patient in Trial of Investigational Wilson Disease Treatment

October 5, 2026 | marketscreener.comM

Prime Medicine Doses First Patient in Global Phase 1/2 Trial of PM577a for Wilson Disease and Receives FDA Rare Pediatric Disease Designation

October 5, 2026 | quiverquant.comQ

Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease

October 5, 2026 | globenewswire.com

What kind of company is Prime Medicine (PRME)? — A gene-editing company where funding outlooks and data timelines "overlap"

October 3, 2026 | note.comN

Prime Medicine (NASDAQ:PRME) Cut to "Sell" at Wall Street Zen

October 3, 2026 | marketbeat.com

Bank of America Corp DE Makes New $3.62 Million Investment in Prime Medicine, Inc. $PRME

September 30, 2026 | marketbeat.com

Prime Medicine (NASDAQ:PRME) Stock Price Up 6.1% - Still a Buy?

September 29, 2026 | marketbeat.com

Prime Medicine Clears FDA Hurdle For Gene-Editing Therapy Targeting Rare Genetic Disease; Stock Up

September 26, 2026 | rttnews.com

Prime Medicine's PM647 Clears Key Regulatory Hurdle, Oppenheimer Says

September 26, 2026 | finance.yahoo.com

Prime: A Buy Due To BLA Filing H1 '27 And Continued PM647 Advancement

September 25, 2026 | seekingalpha.com

Prime Medicine (NASDAQ:PRME) Shares Gap Up - What's Next?

September 25, 2026 | marketbeat.com

Prime Medicine (NASDAQ:PRME) Stock Keeps Buy Rating at Chardan Capital

September 25, 2026 | marketbeat.com

Prime Medicine, Inc.: Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency

September 25, 2026 | finanznachrichten.de

Prime Medicine Shares Jump on FDA Clearance for Investigational New Drug Application

September 24, 2026 | marketscreener.comM

Prime Medicine stock surges on FDA IND clearance

September 24, 2026 | finance.yahoo.com

Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency

September 24, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PEPG, DSGN, PRME, and OLMA Company Descriptions

Design Therapeutics NASDAQ:DSGN

$11.65 +0.16 (+1.39%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$11.65 0.00 (0.00%)

As of 10/9/2026 07:30 PM Eastern

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Olema Pharmaceuticals NASDAQ:OLMA

$7.82 0.00 (0.00%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$7.82 0.00 (-0.06%)

As of 10/9/2026 07:54 PM Eastern

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

PepGen NASDAQ:PEPG

$2.62 +0.24 (+10.08%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$2.54 -0.08 (-3.17%)

As of 10/9/2026 07:30 PM Eastern

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.

Prime Medicine NASDAQ:PRME

$3.99 +0.41 (+11.45%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$3.99 0.00 (-0.10%)

As of 10/9/2026 07:59 PM Eastern

We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology. Genetic mutations implicated in disease are diverse and can range from errors of a single base, known as point mutations, to errors that extend beyond a single base, such as insertions, deletions, duplications, or combinations thereof. We believe the ability to alter the human genome at the foundational level may confer the greatest therapeutic impact on human disease. Gene editing, including platforms such as Prime Editing, is a novel technology that is not yet clinically validated for human therapeutic use. Over the last decade, the field of genetic medicine has evolved tremendously, with groundbreaking advances in gene therapy, cell therapy, RNA therapy, and, more recently, gene editing. These technologies represent dramatic advancements for genetic therapies, but lack the versatility to precisely and efficiently correct the diverse range of mutations or DNA alterations implicated in disease. Prime Medicine was co-founded by a world-renowned leader in the field of gene editing, David Liu, Ph.D. Dr. Liu was joined as co-founder by Andrew Anzalone, M.D., Ph.D., who conceived of and developed Prime Editing technology. Drawn by the promise of Prime Editing’s ability to transform the field of gene editing, we have assembled a diverse team that has grown to more than 150 people as of September 30, 2022. There are no current plans for Dr. Liu to be an officer or director of our company following this offering. He is expected to continue to provide consulting services to us pursuant to a consulting agreement, which has a current term that runs through September 2025 and accommodates a previous commitment with respect to Beam Therapeutics Inc., which could result in or may create the appearance of a conflict of interest. He is also expected to retain his position and affiliation with the Broad Institute, Inc., Howard Hughes Medical Institute and Harvard University. On September 20, 2022, we achieved a major milestone as the United States Patent and Trademark Office, or the USPTO, issued U.S. Patent 11,447,770, or the ‘770 Patent, covering methods of using Prime Editors. The Broad Institute, Inc., or Broad Institute, prepared, filed and prosecuted the ‘770 Patent. While Broad Institute is the owner of the ‘770 Patent, it is exclusively licensed to us under the terms of the license agreement with Broad Institute. The ‘770 Patent is the first issued Prime Editing patent in our licensed patent portfolio and we believe it will be instrumental in protecting our Prime Editing platform and pipeline of gene editing programs. We believe our in-licensed and company-owned Prime Editing technology has transformative potential that could change the course of how disease is treated and overcome the challenges associated with current genetic therapies. We in-license our Prime Editing technology pursuant to a license agreement with Broad Institute. In addition, the license agreement grants us certain rights and licenses under certain patent rights Broad Institute owns or controls, including a license to the ‘770 Patent, which covers Prime Editing technology and expires in 2040. The licenses are limited to the field of prevention or treatment of human disease, and most licenses granted to us under the license agreement are further limited to the prevention or treatment of human disease by editing (including modifying or converting) or targeting DNA ex vivo, in vivo, or through xeno transplantation methods, which we refer to as the Prime Broad Field. We were incorporated under the laws of the State of Delaware in September 2019 under the name Prime Medicine, Inc. Our principal executive offices are located at 21 Erie Street, Cambridge, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PEPG, DSGN, PRME, and OLMA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PEPG, DSGN, PRME, and OLMA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PEPG, DSGN, PRME, and OLMA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PEPG, DSGN, PRME, and OLMA Company Descriptions

Design Therapeutics NASDAQ:DSGN

Olema Pharmaceuticals NASDAQ:OLMA

PepGen NASDAQ:PEPG

Prime Medicine NASDAQ:PRME

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PEPG, DSGN, PRME, and OLMA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PEPG, DSGN, PRME, and OLMA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PEPG, DSGN, PRME, and OLMA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PEPG, DSGN, PRME, and OLMA Company Descriptions

Design Therapeutics NASDAQ:DSGN

Olema Pharmaceuticals NASDAQ:OLMA

PepGen NASDAQ:PEPG

Prime Medicine NASDAQ:PRME

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools